Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Oncology has recently undergone a revolutionary change with widespread adoption of immunotherapy for many cancers. Immunotherapy using monoclonal antibodies against checkpoint molecules, including programmed death (PD)-1, PD ligand (PD-L)1, and cytotoxic T lymphocyte-associated antigen (CTLA)-4, is...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Trends in immunology Ročník 40; číslo 6; s. 511 - 523
Hlavní autoři:	Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.06.2019 Elsevier Limited
Témata:	Adaptive immunity Antigens Autoimmune diseases autoimmunity Cancer immunotherapy Cancer therapies checkpoint blockade Clinical trials Cloning Cytotoxicity Disease Etiology Hepatitis Immune checkpoint Immune system immune-related adverse events Immunoglobulins Immunotherapy Inflammatory bowel disease Inflammatory diseases Lymphocytes Lymphocytes T Melanoma Monoclonal antibodies Oncology tolerance Viral infections checkpoint blockade autoimmunity tolerance cancer immunotherapy immune-related adverse events
ISSN:	1471-4906, 1471-4981, 1471-4981
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!